The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 42.00
Bid: 41.50
Ask: 42.50
Change: -2.10 (-4.76%)
Spread: 1.00 (2.41%)
Open: 43.00
High: 43.75
Low: 42.00
Prev. Close: 44.10
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

25 Feb 2016 16:34

RNS Number : 2112Q
Avacta Group PLC
25 February 2016
 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Avacta Group Plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

CHANGE TO THE NUMBER OF VOTING RIGHTS IN ISSUE, FOLLOWING THE RECENT ISSUE OF EQUITY

3. Full name of person(s) subject to thenotification obligation: iii

Aviva plc & its subsidiaries

4. Full name of shareholder(s)  (if different from 3.):iv

Registered Holder:

 

BNY Norwich Union Nominees Limited

318,650*

 

Chase (GA Group) Nominees Limited

5,552,725*

 

* denotes direct interest

 

Chase (GA Group) Nominees Limited

451,387

 

Chase Nominees Limited

161,558

 

Vidacos Nominees Limited

264,154

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

22 February 2016

6. Date on which issuer notified:

23 February 2016

7. Threshold(s) that is/are crossed orreached: vi, vii

>10% to

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Ordinary Shares

ORD GBP0.010GB00BYYW9G87

Ordinary Shares

GBP0.001GB0033519546

 

675,000,005

Ordinary Shares

GBP0.001GB0033519546

 

675,000,005

6,748,474

5,871,375

877,099

8.59%

1.28%

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

Nominal

Delta

 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

6,748,474

9.87%

 

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

The voting rights are managed and controlled by Aviva Investors Global Services Limited, with the following chain of controlled undertakings:-

 

Aviva Investors Global Services Limited:

· Aviva plc (Parent Company)

· Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc)

· Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited)

· Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited)

 

 

Proxy Voting:

10. Name of the proxy holder:

See Section 4

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

 

13. Additional information:

Figures are based on a total number of voting rights of 68,367,990 as per the Company's Directors' Dealings and Issue of Equity annoucement of 17 February 2016.

 

14. Contact name:

Neil Whittaker, Aviva plc

15. Contact telephone number:

01603 684420

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLFMGZZVKMGVZM
Date   Source Headline
5th Apr 20237:00 amRNSFirst Patient Dosed in Fifth Cohort of AVA6000
3rd Apr 20237:00 amRNSNotice of Results and Investor Presentation
27th Mar 20237:00 amRNSAVA3996 data poster presentation at AACR
13th Mar 20237:00 amRNSStatement re: Silicon Valley Bank
23rd Feb 20237:00 amRNSAvacta Therapeutics Division Science Day
13th Feb 20237:00 amRNSIssue of Equity and Total Voting Rights
23rd Jan 202312:20 pmRNSIssue of Equity and Total Voting Rights
17th Jan 20232:05 pmRNSSecond Price Monitoring Extn
17th Jan 20232:00 pmRNSPrice Monitoring Extension
17th Jan 202311:05 amRNSSecond Price Monitoring Extn
17th Jan 202311:00 amRNSPrice Monitoring Extension
17th Jan 20239:05 amRNSSecond Price Monitoring Extn
17th Jan 20239:00 amRNSPrice Monitoring Extension
17th Jan 20237:00 amRNSSuccessful Completion of Fourth Dose Escalation
16th Jan 202310:15 amRNSBlock Listing Application to AIM
19th Dec 20227:00 amRNSAvacta to Host Therapeutics Division Science Day
8th Nov 20227:01 amRNSDirector/PDMR Shareholding
8th Nov 20227:00 amRNSResult of the Open Offer
31st Oct 20221:32 pmRNSAvacta to Present at Theranostics FAP Summit
31st Oct 202211:05 amRNSSecond Price Monitoring Extn
31st Oct 202211:00 amRNSPrice Monitoring Extension
28th Oct 20227:00 amRNSBlock Listing Six Monthly Return
20th Oct 20228:01 amRNSDirector/PDMR Shareholding
20th Oct 20228:01 amRNSAdmission of the Company’s Ordinary Shares
20th Oct 20227:00 amRNSPosting of the Company’s Open Offer Circular
18th Oct 202211:49 amRNSResult of Placing
18th Oct 20229:16 amRNSPrivate CB and ABB Launch
18th Oct 20229:14 amRNSProposed acquisition of Launch Diagnostics
29th Sep 20227:00 amRNSInterim Results for the Period Ended 30 June 2022
26th Sep 20227:00 amRNSNotice of Results
5th Sep 20227:00 amRNSAVA6000 receives Orphan Drug Designation from FDA
1st Sep 20227:00 amRNSPhase I study of AVA6000 advances to fourth cohort
21st Jul 20227:00 amRNSAffyXell successfully completes funding round
30th Jun 20227:00 amRNSLG Chem renews license triggers payment to Avacta
29th Jun 20229:05 amRNSSecond Price Monitoring Extn
29th Jun 20229:00 amRNSPrice Monitoring Extension
29th Jun 20227:00 amRNSSecond dose escalation in phase 1 trial of AVA6000
23rd Jun 20224:41 pmRNSSecond Price Monitoring Extn
23rd Jun 20224:36 pmRNSPrice Monitoring Extension
23rd Jun 20224:27 pmRNSResult of Annual General Meeting
16th Jun 20224:41 pmRNSSecond Price Monitoring Extn
16th Jun 20224:36 pmRNSPrice Monitoring Extension
31st May 20227:00 amRNSPosting of Annual Report and Notice of AGM
16th May 202212:00 pmRNSAffyXell expands partnership with GenScript ProBio
11th May 20227:00 amRNSLondon Therapeutics headquarters established
6th May 20227:00 amRNSBlock Listing Application to AIM (update)
28th Apr 20221:53 pmRNSBlock Listing Application to AIM
14th Apr 20225:01 pmRNSIssue of Equity and Total Voting Rights
14th Apr 202211:29 amRNSIssue of Equity and Total Voting Rights
13th Apr 20227:00 amRNSAffyXell milestone and increased equity stake

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.